- Home
- HOS vs LBRX Comparison
HOS vs LBRX Comparison
Compare HOS & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HOS | LBRX |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | HOS | LBRX |
|---|---|---|
| Price | $8.98 | $48.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $46.60 |
| AVG Volume (30 Days) | N/A | ★ 273.6K |
| Earning Date | N/A | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 98.22 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | N/A | $13.40 |
| 52 Week High | N/A | $50.16 |
Technical Indicators
Market Signals| Indicator | HOS | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 58.81 |
| Support Level | N/A | $26.13 |
| Resistance Level | N/A | $49.65 |
| Average True Range (ATR) | 0.00 | 2.00 |
| MACD | 0.00 | -0.43 |
| Stochastic Oscillator | 0.00 | 54.23 |
Price Performance
Historical ComparisonAbout LBRX LB Pharmaceuticals Inc
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.